免疫相关不良事件热点问题解析

Clarification of Hot Issues of Immune-Related Adverse Events

以免疫检查点抑制剂(ICIs)为代表的免疫治疗在给恶性肿瘤患者带来良好疗效的同时,也可能会导致免疫相关不良事件(irAEs)。已有较多的国内外指南或共识指导临床医师有效解决绝大多数irAEs。然而irAEs的定义和判定、时间规律、个体差异、激素和免疫抑制剂使用、irAEs与疗效的关系、免疫重启、特殊人群等问题仍有待进一步探讨,重症型、难治性和多重irAEs的识别和处理仍待进一步解决。本文梳理了irAEs的十个热点问题并逐一进行解析,以期给临床医师带来帮助。

Immunotherapy,represented by immune checkpoint inhibitors,may lead to immune-related adverse events(irAEs)while demonstrating favorable efficacy in patients with malignant tumors.Many domestic and international guidelines or consensus have been established to assist clinicians in effectively managing the majority of irAEs.However,further exploration about irAEs is required regarding the definition and determination,temporal patterns,individual variances,utilization of hormones and immunosuppressants,correlation between irAEs and therapeutic outcomes,immune reactivation,and special populations.The identification and management of severe,refractory,and multiple irAEs necessitate additional solutions.This paper aims to clarify 10 prominent issues concerning irAEs individually and provide assistance for clinicians.